Gubra will host its inaugural Investor R&D Event on Tuesday, October 27, 2026, presenting the company’s strategy toward 2030.
The event will highlight Gubra’s differentiated innovation model spanning Biotech, CRO, and Ventures, and provide an update on its R&D pipeline, with a particular focus on GUB-UCN2.
Time: October 27, 2026, starting at 13:00 GMT (14:00 CET)
Venue: Goldman Sachs International
Address: Plumtree Court, 25 Shoe Lane, London EC4A 4AU, United Kingdom
Register for in-person or virtual attendance: https://gubra-rd-event-2026-oct-27.open-exchange.net/
A replay of the webcast will be available on the company’s website following the event.
Speakers
- Markus Rohrwild, Chief Executive Officer
- Kristian Borbos, Chief Financial Officer
- Louise S. Dalbøge, Chief Science Officer
- Thomas Langenickel, Chief Medical and Development Officer
- Zoë Johnson, Head of Gubra Ventures & Business Development
- Trine Nygaard Hamann, Head of Gubra CRO
- Juleen R. Zierath, Professor of Clinical Integrative Physiology at Karolinska Institutet and Executive Director of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen
Contacts at Gubra
Investors and Media: Adam Lange ([email protected], +45 6646 1589)
Investors: Kristian Borbos ([email protected], +45 3080 8035)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025.
See www.gubra.dk for more information.